4/6
09:08 am
zlab
Zai Lab: Xacduro And ZL-1310 Drive Growth Narrative [Seeking Alpha]
Low
Report
Zai Lab: Xacduro And ZL-1310 Drive Growth Narrative [Seeking Alpha]
4/2
10:38 pm
zlab
How Tavneos Safety Risks and New Oncology Pact Could Rebalance Amgen's (AMGN) Risk-Reward Profile [Yahoo! Finance]
Low
Report
How Tavneos Safety Risks and New Oncology Pact Could Rebalance Amgen's (AMGN) Risk-Reward Profile [Yahoo! Finance]
4/1
08:24 am
zlab
Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy [Yahoo! Finance]
Medium
Report
Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy [Yahoo! Finance]
4/1
07:30 am
zlab
Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy
Medium
Report
Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy
3/18
12:25 pm
zlab
Zai Lab (ZLAB) had its price target lowered by JPMorgan Chase & Co. from $39.00 to $32.00. They now have an "overweight" rating on the stock.
Low
Report
Zai Lab (ZLAB) had its price target lowered by JPMorgan Chase & Co. from $39.00 to $32.00. They now have an "overweight" rating on the stock.
3/18
11:22 am
zlab
Nationwide International Small Cap Fund Q4 2025 Commentary [Seeking Alpha]
Low
Report
Nationwide International Small Cap Fund Q4 2025 Commentary [Seeking Alpha]
3/17
05:08 pm
zlab
Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC) [Yahoo! Finance]
Low
Report
Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC) [Yahoo! Finance]
3/17
04:35 pm
zlab
Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC)
Low
Report
Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC)
3/9
05:51 pm
zlab
Neuroendocrine Carcinoma Market Poised for Significant Growth During the Forecast Period (2026-2036) Driven by Rising Incidence and Advancements in Targeted Therapies | DelveInsight [Yahoo! Finance]
Low
Report
Neuroendocrine Carcinoma Market Poised for Significant Growth During the Forecast Period (2026-2036) Driven by Rising Incidence and Advancements in Targeted Therapies | DelveInsight [Yahoo! Finance]
3/1
07:42 am
zlab
Is Zai Lab (ZLAB) Now A Bargain After Recent 15.8% Share Price Jump? [Yahoo! Finance]
Medium
Report
Is Zai Lab (ZLAB) Now A Bargain After Recent 15.8% Share Price Jump? [Yahoo! Finance]
2/27
06:28 pm
zlab
Zai Lab Q4 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
Zai Lab Q4 Earnings Call Highlights [Yahoo! Finance]
2/27
09:47 am
zlab
Zai Lab (ZLAB) had its price target lowered by Cantor Fitzgerald from $55.00 to $37.00. They now have an "overweight" rating on the stock.
Low
Report
Zai Lab (ZLAB) had its price target lowered by Cantor Fitzgerald from $55.00 to $37.00. They now have an "overweight" rating on the stock.
2/26
04:14 pm
zlab
Zai Lab Limited (ZLAB) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates [Yahoo! Finance]
Low
Report
Zai Lab Limited (ZLAB) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates [Yahoo! Finance]
2/26
01:53 pm
zlab
Zai Lab Limited (ZLAB) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
Zai Lab Limited (ZLAB) Q4 2025 Earnings Call Transcript [Seeking Alpha]
2/26
07:24 am
zlab
Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates [Yahoo! Finance]
Low
Report
Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates [Yahoo! Finance]
2/26
07:11 am
zlab
Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update [Yahoo! Finance]
Low
Report
Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update [Yahoo! Finance]
2/26
07:00 am
zlab
Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
Low
Report
Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
2/10
08:43 am
zlab
Zai Lab to Announce Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates on February 26, 2026 [Yahoo! Finance]
Medium
Report
Zai Lab to Announce Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates on February 26, 2026 [Yahoo! Finance]
2/10
08:30 am
zlab
Zai Lab to Announce Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates on February 26, 2026
Medium
Report
Zai Lab to Announce Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates on February 26, 2026
2/5
02:28 pm
zlab
Zai Lab (NASDAQ:ZLAB) had its price target lowered by analysts at JPMorgan Chase & Co. from $46.00 to $39.00. They now have an "overweight" rating on the stock.
Low
Report
Zai Lab (NASDAQ:ZLAB) had its price target lowered by analysts at JPMorgan Chase & Co. from $46.00 to $39.00. They now have an "overweight" rating on the stock.
2/4
01:34 pm
zlab
ClearBridge International Growth ADR Strategy exits Linde, adds Roche in Q4 2025 [Seeking Alpha]
Low
Report
ClearBridge International Growth ADR Strategy exits Linde, adds Roche in Q4 2025 [Seeking Alpha]
1/30
02:18 am
zlab
UBS Sees Zai Lab (ZLAB) as a Rising Global Biopharma Platform [Yahoo! Finance]
Low
Report
UBS Sees Zai Lab (ZLAB) as a Rising Global Biopharma Platform [Yahoo! Finance]
1/27
05:58 am
zlab
Zai Lab (NASDAQ:ZLAB) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Medium
Report
Zai Lab (NASDAQ:ZLAB) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
1/23
05:09 am
zlab
Zai Lab (NASDAQ:ZLAB) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Zai Lab (NASDAQ:ZLAB) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/20
06:59 am
zlab
Zai Lab (NASDAQ:ZLAB) was upgraded by analysts at Jefferies Financial Group Inc. to a "strong-buy" rating.
Low
Report
Zai Lab (NASDAQ:ZLAB) was upgraded by analysts at Jefferies Financial Group Inc. to a "strong-buy" rating.